Brokerages Set Aemetis, Inc. (NASDAQ:AMTX) Price Target at $12.95

Aemetis, Inc. (NASDAQ:AMTX) has earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $12.95.

Several research firms have issued reports on AMTX. HC Wainwright reaffirmed a “buy” rating and set a $28.00 price target on shares of Aemetis in a research note on Friday, August 2nd. UBS Group cut their price target on Aemetis from $8.25 to $7.75 and set a “buy” rating for the company in a report on Monday, August 19th. Truist Financial reissued a “hold” rating and set a $3.50 price target (down previously from $4.00) on shares of Aemetis in a research note on Wednesday, July 31st. StockNews.com raised Aemetis to a “sell” rating in a research report on Wednesday, July 31st. Finally, Ascendiant Capital Markets reduced their target price on Aemetis from $20.00 to $19.00 and set a “buy” rating on the stock in a research report on Tuesday, September 3rd.

Institutional Investors Weigh In On Aemetis

Institutional investors have recently added to or reduced their stakes in the company. Susquehanna Fundamental Investments LLC increased its stake in Aemetis by 287.4% during the second quarter. Susquehanna Fundamental Investments LLC now owns 126,078 shares of the specialty chemicals company’s stock worth $379,000 after acquiring an additional 93,536 shares during the last quarter. Hutchinson Capital Management CA purchased a new position in Aemetis in the second quarter valued at approximately $70,000. Rhumbline Advisers lifted its position in Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock valued at $157,000 after buying an additional 50,528 shares in the last quarter. Bank of New York Mellon Corp acquired a new position in Aemetis during the second quarter valued at approximately $306,000. Finally, State Board of Administration of Florida Retirement System acquired a new stake in shares of Aemetis in the first quarter worth $84,000. Hedge funds and other institutional investors own 27.02% of the company’s stock.

Aemetis Price Performance

Shares of Aemetis stock opened at $2.47 on Friday. The business has a 50 day moving average price of $2.59 and a 200 day moving average price of $3.41. The company has a market capitalization of $109.66 million, a P/E ratio of -2.11 and a beta of 1.25. Aemetis has a 1 year low of $2.10 and a 1 year high of $7.03.

Aemetis (NASDAQ:AMTX) last posted its quarterly earnings data on Thursday, August 1st. The specialty chemicals company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.25). The company had revenue of $66.56 million during the quarter, compared to analyst estimates of $75.37 million. During the same quarter in the prior year, the firm posted ($0.68) earnings per share. As a group, research analysts expect that Aemetis will post -2.19 EPS for the current fiscal year.

About Aemetis

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.